Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
PMID: 39246720
Imagine Drucker submitting a grant proposal today titled "Investigating Gila Monster Venom Proteins for Potential Therapeutic Applications." How would reviewers respond to: Unclear commercial potential No obvious connection to existing treatment paradigms High risk of "failure" (most venom studies don't yield drugs) Difficult to measure short-term impact Traditional funding metrics, publication counts, citation indices, immediate clinical relevance, would likely work against such proposals
As our bodies age, and depending on our environmental conditions, our natural abilities to produce many compounds like glutathione can slow down and become weaker
Retatrutide is a new weight loss drug from Eli Lilly and has promising results in clinical trials but is not yet available
The press release notes that oral GLP-1 medications (if FDA-approved, such as the Wegovy pill) would have an initial dose priced at $149/month through TrumpRX
Profile 3: Poorly Controlled or Unstable Psychiatric Illness Semaglutide and tirzepatide carry no specific psychiatric black box warning, but the FDA's Adverse Event Reporting System (FAERS) contains post-marketing reports of suicidal ideation associated with GLP-1 agents, prompting the FDA to open a signal evaluation in 2023 [7]
US$ 23.02
US$ 28.23
US$ 23.23
US$ 20.87
US$ 25.37
US$ 29.75
US$ 27.37
US$ 22.32
US$ 29.62
US$ 25.86
